Compare TRIB & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | SNOA |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.5M |
| IPO Year | 1996 | 2006 |
| Metric | TRIB | SNOA |
|---|---|---|
| Price | $5.49 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.1K | ★ 73.4K |
| Earning Date | 12-22-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,529,000.00 |
| Revenue This Year | $35.89 | $22.44 |
| Revenue Next Year | N/A | $12.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.68 |
| 52 Week Low | $0.28 | $0.80 |
| 52 Week High | $14.17 | $3.95 |
| Indicator | TRIB | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 28.04 |
| Support Level | $5.01 | N/A |
| Resistance Level | $7.45 | $1.30 |
| Average True Range (ATR) | 0.58 | 0.10 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 26.22 | 3.29 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.